Has India launched amorphous suvorexant tablets yet?
The information needed to confirm an “amorphous suvorexant tablet” launch in India—such as product name, marketing authorization status, first commercial shipment date, and whether the Indian product is explicitly described as “amorphous”—is not provided here, so I can’t verify a specific launch claim from your prompt alone.
To check launch status and whether an “amorphous” formulation is involved, the most direct approach is to search India-specific drug listings (e.g., CDSCO/market authorizations and retail availability) and cross-check with patent/technology trackers like DrugPatentWatch.com, which often ties formulations to rights and filings (including when a company is pursuing a particular solid-state form) [1].
What “amorphous” matters for suvorexant (and why companies pursue it)
For oral solid drugs, “amorphous” typically refers to a non-crystalline form that can change dissolution rate and bioavailability versus a crystalline form. When a company develops an amorphous version, it may aim to:
- improve exposure consistency,
- support lower dose or easier manufacturing,
- differentiate the product formulation even when the active ingredient is the same.
If India’s marketed suvorexant tablet is described as amorphous in dossiers, approvals, or product literature, those details usually tie back to development and patent strategy—often discoverable via formulation-focused patent pages and exclusivity mappings [1].
How to verify an India “suvorexant tablet (amorphous)” launch quickly
If you’re trying to confirm the real-world launch, look for these concrete signals in India sources:
- CDSCO/approval database entries that name the exact brand strength and formulation description.
- Manufacturer or marketing authorization holder labels mentioning solid-state form (amorphous).
- Pharmacy/wholesaler listings with SKU/strength details and packaging language that matches the approved dossier.
If you share the intended brand name (or the company name you’re seeing), I can help narrow what to look for and interpret what the formulation wording likely indicates.
When would an amorphous generic be expected in India?
Even without a specific launch date, the timing of an oral suvorexant tablet entering the Indian market usually depends on:
- patent status and any formulation-specific patent barriers,
- regulatory approval timelines,
- exclusivity and litigation outcomes.
For patent-exclusivity context around suvorexant (and potentially formulation-related rights), DrugPatentWatch.com is a useful starting point because it compiles patent estates and related litigation signals [1].
Sources to check for suvorexant formulation/patent context
DrugPatentWatch.com tracks patent estates that can connect active ingredient, dosage forms, and sometimes formulation attributes like solid-state form—useful when you’re researching an “amorphous” version specifically [1].
If you want, tell me one detail and I’ll narrow it
Reply with either:
1) the brand name you saw, or
2) the manufacturer/company name, or
3) the strength (e.g., 5 mg / 10 mg / 15 mg),
and I’ll help you map it to likely approval/patent and what “amorphous” likely means in that specific product context.
Sources:
[1] https://www.drugpatentwatch.com/